
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The von Hippel-Lindau disease market is expected to grow at a CAGR of 7.97% during the forecast period of 2025-2034, driven by the increased research and clinical trials for effective treatments across the 8 major markets.
Base Year
Historical Year
Forecast Year
Von Hippel-Lindau disease or von Hippel-Lindau syndrome refers to a rare genetic disorder that causes the formation of tumors and fluid-filled sacs (cysts). The condition occurs due to a mutation in the VHL gene that codes for a protein regulating cell division. In von Hippel-Lindau disease patients, the faulty VHL protein can lead to uncontrolled cell growth and tumors. The rising advancements in targeted therapies and other treatment options that address multiple manifestations of the disease, including renal cell carcinoma and pheochromocytoma, are expected to support the market growth. Increased awareness about von Hippel-Lindau disease and the availability of genetic testing are further anticipated to boost the market demand. Moreover, the growing emphasis on multidisciplinary care approaches and combination therapies is likely to influence the market dynamics.
Rising Adoption of Targeted Therapies to Impact Market Growth
In October 2023, Scotland became the first European country to accept the use of Merck Sharp & Dohme’s Welireg (belzutifan), a hypoxia-inducible factor inhibitor, for eligible adult patients affected by von Hippel-Lindau (VHL) disease. Further, in September 2024, the National Health Service (NHS) England announced the availability of MSD’s belzutifan take-at-home oral pill for von Hippel-Lindau disease patients. The rising acceptance and adoption of targeted therapies that address the underlying genetic mutations causing the disease are expected to impact the market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class:
Market Breakup by Tumor Site:
Market Breakup by Route of Administration:
Market Breakup by End User:
Market Breakup by Region:
The Tumor Site Segment Represents a Substantial Market Share
Based on the tumor site, the market is segmented into brain, spinal cord, eyes, kidneys, adrenal glands, pancreas, liver, lungs, reproductive tract and others. Kidneys are one of the most common and severe manifestations observed in von Hippel-Lindau disease patients. It poses as a serious cause of morbidity and mortality. The development of targeted therapies such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors for the management of von Hippel-Lindau disease-associated renal cell carcinoma is likely to support the growth of this segment. Further, the increasing prevalence of renal cell carcinoma and the rising adoption of precision medicine are likely to impact the market share of the segment in the coming years.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States leads the market for von Hippel-Lindau disease owing to its strong focus on oncology and rare disease research and the presence of major companies like Bristol Myers Squibb and Exelixis actively involved in drug development for the condition. The increase in the number of clinical trials and supportive regulatory frameworks for rare disease drugs are also anticipated to fuel the market growth. Moreover, the country's advanced healthcare infrastructure and collaborative research initiatives are poised to aid the market expansion in the forecast period.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2024 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Tumor Site |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share